Question 1

How does semaglutide compare to tirzepatide?

Accepted Answer

Tirzepatide is a dual GIP/GLP-1 agonist and has shown greater weight-loss magnitude in head-to-head and network analyses (SURMOUNT-5 reported approximately 20% mean weight reduction vs ~15% for semaglutide). Side-effect profiles are broadly similar.

Question 2

What is the cardiovascular evidence?

Accepted Answer

The SELECT trial (2023) showed a 20% reduction in three-point MACE in overweight/obese adults with established CV disease but without diabetes — a first-in-class non-diabetic CV benefit for GLP-1 agonism.

Question 3

Is oral semaglutide equivalent to the injectable?

Accepted Answer

Oral semaglutide (Rybelsus) requires SNAC co-formulation for absorption; bioavailability is low (<1%) but reproducible under fasted dosing rules. Weight-loss magnitude is typically lower than the 2.4 mg injectable dose.

Question 4

What is CagriSema and how does it compare?

Accepted Answer

CagriSema combines semaglutide 2.4 mg with cagrilintide (a long-acting amylin analog). Phase 3 trials showed ~24% weight loss — substantially more than semaglutide alone (~16%). It targets two independent satiety pathways (GLP-1 + amylin).

Question 5

Does weight come back after stopping semaglutide?

Accepted Answer

Yes — the STEP 1 extension trial showed approximately two-thirds of lost weight was regained within one year of discontinuation. Semaglutide manages appetite; it does not permanently reset body weight set point. Most clinicians consider it a chronic therapy.

Question 6

What about muscle loss on semaglutide?

Accepted Answer

Approximately 25-40% of weight lost on GLP-1 agonists is lean mass, consistent with any significant caloric deficit. Resistance training and adequate protein intake (1.2-1.6 g/kg/day) during treatment are recommended to preserve muscle.

Question 7

Can compounded semaglutide replace brand-name Ozempic or Wegovy?

Accepted Answer

Compounded semaglutide is available from 503B pharmacies during the FDA-declared shortage period. Quality varies by pharmacy — look for facilities with third-party testing, GMP compliance, and transparent purity certificates. Compounded versions may use the salt form (semaglutide sodium) which has slightly different dosing equivalency. When brand-name supply normalizes, FDA has indicated it may restrict compounding.

Question 8

What are the long-term effects of semaglutide beyond 2 years?

Accepted Answer

The STEP-5 trial provides 2-year continuous-use data: weight loss is maintained at approximately 15% with ongoing use. The SELECT trial (3.5 years) confirms sustained cardiovascular benefit. Longer-term data continues to accumulate. There are no identified delayed-onset safety signals beyond the known GI side effects and rare pancreatitis risk, but as with any relatively new chronic therapy, ongoing pharmacovigilance applies.

Question 9

Does semaglutide affect liver health (NAFLD/NASH)?

Accepted Answer

Yes — positively. The phase 2b trial in NASH showed significant histological improvement with semaglutide 2.4 mg (59% NASH resolution vs 17% placebo). Weight loss contributes, but GLP-1 receptors in hepatocytes may provide direct hepatoprotective effects. Semaglutide is being positioned as a potential NASH therapy, though it's not yet approved for this indication specifically.

Question 10

Is semaglutide safe with a history of thyroid cancer?

Accepted Answer

GLP-1 agonists carry a boxed warning for medullary thyroid carcinoma (MTC) based on rodent studies showing C-cell tumors. Human epidemiological data has not confirmed increased thyroid cancer risk, but the warning remains. Semaglutide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). For other thyroid cancer types, discuss with your oncologist — the risk appears specific to C-cell pathology.

Question 11

What strategies help prevent muscle loss while on semaglutide?

Accepted Answer

Muscle preservation during semaglutide therapy requires a multi-pronged approach centered on resistance training and protein optimization. Current evidence recommends progressive resistance exercise at least 3 times per week, targeting all major muscle groups, combined with daily protein intake of 1.2–1.6 g/kg of ideal body weight distributed across meals. Leucine-rich protein sources (whey, eggs, poultry) are particularly effective at stimulating muscle protein synthesis during a caloric deficit. Some clinicians also recommend creatine monohydrate (3–5 g/day) as an adjunct, given its well-established role in preserving lean mass during energy restriction. Monitoring body composition via DXA scans every 3–6 months — rather than relying solely on scale weight — helps distinguish fat loss from lean mass loss and allows protocol adjustments before significant muscle is lost.

Question 12

How does compounded semaglutide differ from brand-name Ozempic or Wegovy?

Accepted Answer

Compounded semaglutide is produced by 503A or 503B compounding pharmacies during FDA-declared drug shortages and may use the semaglutide sodium salt form rather than the free-base form found in brand-name products. This salt-form difference means milligram-for-milligram dosing is not directly equivalent — semaglutide sodium has a higher molecular weight, so a slightly larger dose may be needed for bioequivalence, though standardized conversion factors are still debated. Brand-name products undergo rigorous FDA manufacturing oversight with batch-to-batch consistency, whereas compounding pharmacy quality varies significantly. Patients considering compounded versions should verify the pharmacy holds 503B outsourcing facility registration, conducts third-party potency and sterility testing, and provides certificates of analysis. When brand supply normalizes, FDA has signaled it may curtail compounding authorization, so long-term availability is uncertain.

Question 13

What is the evidence for semaglutide's cardiovascular benefits?

Accepted Answer

The cardiovascular evidence for semaglutide is now among the strongest of any obesity medication. The SELECT trial (2023) enrolled over 17,600 overweight or obese adults with established cardiovascular disease but without diabetes and demonstrated a 20% relative risk reduction in three-point MACE (cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) over a median 3.3-year follow-up. This benefit appeared to extend beyond what weight loss alone would predict, suggesting direct anti-inflammatory and anti-atherosclerotic effects of GLP-1 receptor agonism on vascular endothelium and immune cells. Earlier, the SUSTAIN-6 trial had shown a similar MACE reduction in patients with type 2 diabetes. These findings led to a label expansion making Wegovy the first obesity drug with an FDA-approved cardiovascular risk reduction indication.

Question 14

What should patients know about switching from tirzepatide to semaglutide?

Accepted Answer

Switching from tirzepatide to semaglutide is sometimes necessary due to insurance coverage changes, supply issues, or side-effect management, but it requires careful dose conversion since the two agents are not milligram-equivalent. There is no official conversion table, but clinical practice generally maps tirzepatide 5 mg to approximately semaglutide 0.5–1.0 mg, tirzepatide 10 mg to semaglutide 1.7–2.0 mg, and tirzepatide 15 mg to semaglutide 2.4 mg. Patients switching should expect some weight regain during the transition period because tirzepatide's dual GIP/GLP-1 mechanism provides greater weight-loss efficacy than GLP-1 agonism alone. GI side effects may transiently worsen or change character as the receptor activation profile shifts. Most clinicians recommend a direct switch without a washout period, starting semaglutide at the mapped-equivalent dose and titrating based on tolerability and response over the following 4–8 weeks.

Question 15

How does semaglutide compare to newer GLP-1/glucagon dual agonists like mazdutide?

Accepted Answer

Semaglutide is a pure GLP-1 receptor agonist, while mazdutide and survodutide add glucagon receptor activity on top of GLP-1. The glucagon arm is intended to raise energy expenditure and promote hepatic fat oxidation, which may enhance fat loss and liver-fat reduction beyond GLP-1 alone. Semaglutide has by far the larger approval footprint and long-term outcomes data; the dual agonists are mostly investigational (mazdutide is approved in China but not by the FDA or EMA). For most people, the choice today is between approved agents rather than between mechanisms.

Question 16

What is a 'biased' GLP-1 agonist like ecnoglutide, and is it different from semaglutide?

Accepted Answer

GLP-1 receptors can signal through more than one internal pathway — principally cAMP (which drives insulin secretion and appetite suppression) and beta-arrestin (linked to receptor internalization). Ecnoglutide is engineered to favor cAMP signaling while reducing beta-arrestin recruitment, with the goal of a durable response. Semaglutide is a standard, non-biased agonist. Whether the biased design produces a clinically meaningful advantage over semaglutide has not been established by direct comparison.

Question 17

Why does the dose have to be escalated slowly instead of starting at the effective dose?

Accepted Answer

Semaglutide is titrated gradually — typically starting at 0.25 mg weekly and stepping up over weeks — because the gastrointestinal side effects (nausea, vomiting, constipation) are strongly dose- and speed-dependent. Starting at a full therapeutic dose would provoke intolerable GI symptoms in most people and drive early discontinuation. Slow escalation lets the gut adapt to delayed gastric emptying and central appetite effects, so the same dose that would be intolerable if started abruptly is usually well tolerated when reached gradually. The starting and intermediate doses are not meant to be maximally effective; they are tolerability-building steps. Rushing titration is one of the most common reasons people abandon treatment unnecessarily.

Question 18

How should a missed weekly dose of semaglutide be handled?

Accepted Answer

Because semaglutide has a half-life of roughly one week, a single missed dose does not cause blood levels to collapse immediately, which gives some flexibility. General guidance for the once-weekly injection is that a missed dose can be taken as soon as it is remembered if the next scheduled dose is still several days away; if it is close to the time of the next dose, the missed one is usually skipped rather than doubled up. Doubling doses to 'catch up' is not advised because it increases GI side effects without benefit. After a longer gap of missed doses, a clinician may recommend restarting at a lower dose and re-titrating rather than resuming at the previous level. Specific timing should follow the product labeling and prescriber instructions.

Question 19

How does semaglutide compare to newer combination drugs like CagriSema?

Accepted Answer

CagriSema uses semaglutide as its GLP-1 backbone and adds the amylin analog cagrilintide, and in trials the combination generally produced greater weight loss than semaglutide alone — evidence that adding amylin agonism increases effect. The key difference is status: semaglutide is approved and extensively validated, while CagriSema remains investigational and unapproved. For treatment today, semaglutide is the proven option; CagriSema and the single-molecule GLP-1/amylin co-agonist amycretin are promising but experimental successors.

Dose Range	Ozempic: 0.25–2 mg weekly; Wegovy: up to 2.4 mg weekly
Origin / Manufacturer	Recombinant / synthetic
Regulatory Status	FDA-approved (Ozempic, Wegovy, Rybelsus)
Active Components	Semaglutide
Storage	Refrigerate 2–8°C; in-use pen stable at room temperature for 56 days
Form Factor	Prefilled pen (weekly subcutaneous) or oral tablet

Semaglutide

Specifications

Frequently Asked Questions

Sources & References

Related Peptides

Cagrilintide

Liraglutide

Retatrutide

Tesamorelin

Tirzepatide